Tag Archives: Lexicon

March, 2017

  • 1 March

    FDA Approves Lexicon’s Xermelo for Carcinoid Syndrome Diarrhea

    The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) …

September, 2016

  • 15 September

    FDA Extends PDUFA Date for Lexicon’s Carcinoid Syndrome Drug

    THE WOODLANDS, Texas, Sept. 14, 2016 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (“FDA”) will require additional time to complete its review of the New Drug Application (“NDA”) for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome.  In …

  • 9 September

    Lexicon’s T1D Drug Meets Primary Endpoint in Late-Stage Study

    THE WOODLANDS, Texas, Sept. 9, 2016 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 24 weeks in patients with type 1 diabetes on a background of optimized …